Phytochemical Screening and

Antihyperglycaemic Activities of

Cordyceps Sinensis and Its Based Product

(esulin) by Ab Rahman, Farah ‘Atiqah
PHYTOCHEMICAL SCREENING AND 
ANTIHYPERGLYCAEMIC ACTIVITIES OF 
Cordyceps sinensis AND ITS BASED PRODUCT 
(ESULIN) 
 
 
 
 
 
FARAH ‘ATIQAH BINTI AB RAHMAN 
 
 
 
 
 
 
 
UNIVERSITI SAINS MALAYSIA 
 
2016 
PHYTOCHEMICAL SCREENING AND 
ANTIHYPERGLYCAEMIC ACTIVITIES OF 
Cordyceps sinensis AND ITS BASED PRODUCT 
(ESULIN) 
 
 
 
by 
 
FARAH ‘ATIQAH BINTI AB RAHMAN 
 
 
 
Thesis submitted in fulfilment of the requirements  
for the degree of  
Master of Science 
 
 
 
September 2016 
ii 
 
ACKNOWLEDGEMENTS 
 
In the Name of Allah, The Most Gracious and Most Merciful. May peace and 
blessing be upon our prophet Muhammad S.A.W. 
Alhamdullilah, for the strength and everything He has granted in making this study 
successful. 
 
First and foremost, i would like to take this opportunity to convey my deepest and 
grateful thanks to my main supervisor, Dr. Wan Ezumi binti Mohd Puad @ Mohd 
Fuad for her constructive planning, monitoring, guidance, patience and continuous 
support in the completion of this study. Her guidance influenced me in every way to 
complete my postgraduate study and also special thanks for spending her time to read 
and review my thesis. I also greatly thanks to my co-supervisor, Dr. Dasuki bin 
Sul‟ain and Prof. Dr Aziz Al-Safi bin Ismail for their comment and suggestions. 
 
My grateful thanks to Mr. Mohd Faizul Ismail Che Adam, Mr. Zali Kasim, all staff 
members of Animal Research and Service Center (ARASC), Universiti Sains 
Malaysia and the laboratory staff for their assistance, cooperation and learning 
opportunities given which helped me in completing my research works. 
 
My gratitude and appreciation to fellow colleagues in School of Health Sciences who 
contributed their helped, guidance and moral support throughout in completing my 
study. Your presence is greatly missed and our hardship together is memorable. 
 
Finally, my special thanks to my lovely husband, Mohd Hazlami bin Hishamuddin 
and my parents, Ab Rahman bin Mohamad and Rohani binti Che Mamat who has 
been very understood, helped, patience and supportive throughout the completion my 
iii 
 
research and thesis. Thanks also to my brothers (Mohd Fakhrul Nizam and Mohd 
Nasrul Hakim), sister (Fatin Athirah), sister-in-law (Noziah), niece (Damia Hasya) 
and nephew (Umar Athif) for their continuous believe in me and undeniable 
encouragement throughout my life. Thank you so much for always be there for me 
when it matters most. 
 
Special acknowledgement is also given to Ministry of Higher Education for 
providing financial MyMaster fund for semester fee and Aifa Health SDN. BHD for 
sponsored and support my study. 
  
iv 
 
TABLE OF CONTENTS 
 
ACKNOWLEDGEMENTS ii 
TABLE OF CONTENTS iv 
LIST OF TABLES ix 
LIST OF FIGURES xi 
LIST OF PLATES xii 
LIST OF SYMBOLS AND ABBREVIATIONS xiii 
ABSTRAK xvi 
ABSTRACT xviii 
CHAPTER 1: INTRODUCTION 1 
1.1    Background 
1.2    Scope of the study 
1.3    Objective of the study 
1.3.1    General objective 
1.3.2    Specific objective 
1.4    Importance of the study      
1 
4 
6 
6 
6 
7 
CHAPTER 2: LITERATURE REVIEW 10 
2.1    Diabetes mellitus 
2.1.1    Major classification of diabetes mellitus 
2.1.1.1    Type 1 diabetes mellitus 
2.1.1.2    Type 2 diabetes mellitus 
2.1.1.3    Gestational diabetes mellitus 
2.1.1.4    Other specific types of diabetes mellitus 
2.1.2    Diagnosis of diabetes mellitus 
2.1.3    Symptoms of diabetes mellitus 
2.1.4    Complications associated with diabetes mellitus 
10 
12 
14 
15 
16 
17 
20 
22 
22 
v 
 
2.2    Management of diabetes mellitus 
2.2.1   Oral antidiabetic agents (Insulin secretagogues) 
2.2.1.1    Sulfonylurea 
2.2.1.2    Meglitinides 
2.2.2    Oral antidiabetic egents (Insulin sensitizers) 
2.2.2.1    Biguanides 
2.2.2.2    Thiazolidinediones 
2.2.3    Oral antidiabetic agents (Alpha glucosidase inhibitor) 
2.2.4    Insulin treatment 
2.3    Herbal medicine 
2.3.1    Medicinal herbs used for diabetes mellitus 
2.3.2    Cordyceps sinensis 
2.3.3     Herbal formulations (Esulin) 
2.4    Animal model of diabetes mellitus 
2.4.1    Chemical for induction of diabetic model 
25 
27 
27 
28 
29 
29 
31 
32 
33 
36 
36 
41 
45 
47 
47 
CHAPTER 3: MATERIALS AND METHODS 50 
3.1    Plant materials 
3.2    Preparation of aqueous extracts 
3.3    Study I: Screening of phytochemicals of the aqueous extracts of  
C.sinensis and its based product, Esulin 
 
3.3.1    Test for alkaloids 
3.3.2    Test for saponins 
3.3.3    Test for tannins 
3.3.4    Test for terpenoids (Salkowski test) 
3.3.5    Test for flavonoids 
 
50 
50 
53 
 
53 
53 
54 
54 
54 
vi 
 
3.4    Study II: In vitro antidiabetic activity of the aqueous extracts of 
C.sinensis and its based product, Esulin 
 
3.4.1    Alpha amylase inhibition assay 
3.4.2    Alpha glucosidase inhibition assay 
3.4.3    Statistical analysis 
3.5    Study III: In vivo antidiabetic activity of the aqueous extracts of 
C.sinensis and its based product, Esulin 
 
3.5.1    Pilot study 
3.5.2    Actual study 
 3.5.2.1    Dosage preparation of extracts and drugs 
 3.5.2.2    Experimental animals 
 3.5.2.3    Induction of experimental diabetes  
 3.5.2.4    Study design and dosages 
 3.5.2.5    General observation of rats 
 3.5.2.6    Determination of fasting blood glucose (FBG) 
 3.5.2.7    Biochemical analysis 
 3.5.2.8    Parameters of study 
 3.5.2.9    Statistical analysis 
56 
 
56 
57 
58 
60 
 
60 
60 
60 
61 
61 
62 
63 
63 
63 
64 
64 
CHAPTER 4: RESULTS 66 
4.1    Corticosteroid analysis 
4.2    Study I: Screening of phytochemicals of the aqueous extracts of 
C.sinensis and its based product, Esulin 
 
4.3  Study II: In vitro antidiabetic activity of the aqueous extracts of 
C.sinensis and its based product, Esulin 
 
4.3.1    Alpha amylase inhibition assay 
4.3.2    Alpha glucosidase inhibition assay 
66 
67 
 
68 
 
68 
72 
vii 
 
4.4    Study III: In vivo antidiabetic activity of the aqueous extracts of 
C.sinensis and its based product, Esulin 
 
4.4.1    General observation of rats 
4.4.2    Body weight  
4.4.3    Fasting blood glucose (FBG) 
4.4.4    Fasting serum fructosamine 
4.4.5    Fasting serum insulin 
4.4.6    Lipid profile 
4.4.6.1    Total cholesterol level 
4.4.6.2    Triglycerides level 
4.4.6.3     High Density Lipoprotein-cholesterol level 
4.4.7    Renal function test 
4.4.8    Liver function test 
75 
 
75 
76 
78 
80 
82 
84 
84 
84 
85 
87 
89 
CHAPTER 5: DISCUSSIONS 92 
5.1    Study I: Screening of phytochemicals of the aqueous extracts of 
C.sinensis and its based product, Esulin 
 
5.2    Study II: In vitro antidiabetic activity of the aqueous extracts of 
C.sinensis and its based product, Esulin 
 
5.2.1    Alpha amylase and alpha glucosidase inhibitors 
5.3    Study III: In vivo antidiabetic activity of the aqueous extracts of 
C.sinensis and its based product, Esulin 
 
5.3.1    Health status and body weight of rats 
5.3.2    Fasting blood glucose of rats 
5.3.3    Fasting serum fructosamine of rats 
5.3.4    Fasting serum insulin of rats 
5.3.5    Lipid profile of rats 
93 
 
97 
 
97 
100 
 
100 
103 
108 
109 
111 
viii 
 
5.3.6    Renal and liver function tests 
5.4    Overall discussion 
112 
117 
CHAPTER 6: CONCLUSION AND RECOMMENDATIONS  120 
6.1    Conclusion 
6.2    Recommendations for future research 
120 
121 
REFERENCES 123 
APPENDICES  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ix 
 
LIST OF TABLES 
      
                                                                                                       
 
Table 2.1: 
 
Table 2.2: 
 
Table 2.3: 
 
 
Table 2.4: 
 
 
Table 2.5: 
 
Table 2.6: 
 
 
Table 2.7: 
 
 
Table 2.8: 
 
Table 2.9: 
 
 
Table 3.1 
 
 
 
Table 3.2 
 
 
Table 3.3 
 
 
Table 4.1: 
 
 
Table 4.2: 
 
 
Table 4.3: 
 
 
Table 4.4: 
 
 
 
 
Comparison between type 1 and type 2 diabetes mellitus 
Other specific types of diabetes mellitus 
 
The 1999 World Health Organization diagnostic criteria 
for diabetes 
 
Treatment status of patients with diabetes mellitus in 
Malaysia 
 
Currently available insulin formulation 
 
Some of antidiabetic plants used for treatment of diabetes 
mellitus 
 
Pharmacological studies on the effects of Cordyceps 
sinensis extracts 
 
The comparison between streptozotocin and alloxan 
 
The doses of various chemical diabetogens in different 
species 
 
List of chemicals and laboratory equipments used in the 
preparation of extracts and phytochemical screening in the 
Study I 
 
List of chemicals and laboratory equipments used in the 
Study II 
 
List of chemicals and laboratory equipments used in the 
Study III 
 
Corticosteroid screening of the aqueous extracts of 
C.sinensis and Esulin 
 
Qualitative phytochemical analysis of the aqueous extracts 
of C.sinensis and Esulin  
 
IC50 value for in vitro alpha amylase inhibition by 
C.sinensis, Esulin and acarbose 
 
IC50 value for in vitro alpha glucosidase inhibition by 
C.sinensis, Esulin and acarbose 
 
 
 
13 
 
18 
 
21 
 
 
26 
 
 
35 
 
38 
 
 
43 
 
 
48 
 
49 
 
 
55 
 
 
 
59 
 
 
65 
 
 
66 
 
 
67 
 
 
71 
 
 
74 
 
 
 
Page 
x 
 
Table 4.5: 
 
 
Table 4.6: 
 
 
Table 4.7: 
Effects of herbal extracts and standard drugs on lipid 
profile of streptozotocin-induced diabetic rats 
 
Effects of herbal extracts and standard drugs on renal 
function of streptozotocin-induced diabetic rats 
 
Effects of herbal extracts and standard drugs on liver 
function of streptozotocin-induced diabetic rats 
86 
 
 
88 
 
 
91 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xi 
 
LIST OF FIGURES 
                                                                                                           
                                                                                                                                                                                                            
Figure 1.1: 
 
 
 
Figure 2.1: 
 
Figure 4.1: 
 
 
Figure 4.2: 
 
 
Figure 4.3: 
 
 
 
Figure 4.4: 
 
 
 
Figure 4.5: 
 
 
 
 
Figure 4.6: 
Experimental design of the overall study. This experiment 
comprised of phytochemical, in vitro and in vivo studies of 
Cordyceps sinensis and its based product, Esulin. 
 
Prevalence of diabetes mellitus by age group in Malaysia 
 
Percentage inhibitory effects of C.sinensis, Esulin and 
acarbose on alpha amylase activity 
 
Percentage inhibitory effects of C.sinensis, Esulin and 
acarbose on alpha glucosidase activity 
 
Effects of herbal extracts (C.sinensis (CS) & Esulin) and 
standard drugs (Metformin & Humulin R) on body weight 
of STZ- induced diabetic rats 
 
Effects of herbal extracts (C.sinensis (CS) & Esulin) and 
standard drugs (Metformin & Humulin R) on fasting blood 
glucose of STZ-induced diabetic rats 
 
Effects of herbal extracts (C.sinensis (CS) & Esulin) and 
standard drugs (Metformin & Humulin R) on fasting serum 
fructosamine of STZ-induced diabetic rats during 
sacrificed 
 
Effects of herbal extracts (C.sinensis (CS) & Esulin) and 
standard drugs (Metformin & Humulin R) on fasting serum 
insulin of STZ-induced diabetic rats during sacrificed 
 
 
 
 
 
 
 
 
9 
 
 
 
11 
 
70 
 
 
73 
 
 
77 
 
 
 
79 
 
 
 
81 
 
 
 
 
83 
 
 
 
 
 
 
  Page 
xii 
 
LIST OF PLATES 
                                                                                                         
                                                                                                        
Plate 2.1: 
 
Plate 2.2: 
 
 
Plate 3.1: 
 
 
 
 
 
A photograph of Cordyceps sinensis 
 
A photograph of Esulin powder used in the current 
experiment 
 
a) A photograph of aqueous extract of Cordyceps sinensis 
b) A photograph of aqueous extract of Esulin 
 
 
 
44 
 
46 
 
 
52 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Page 
xiii 
 
LIST OF SYMBOLS AND ABBREVIATIONS 
 
ALP 
ALT 
ALX 
ANOVA 
Anti-GAD 
ARASC 
AST 
BMI 
BUN 
CS 
DALYs 
DM 
DNS 
FBG 
FFA 
FPG 
GC-MS 
GDM 
H2SO4 
HbA1c 
HCL 
HDL 
IC50 
Alkaline phosphatase 
Alkaline aminotransferase 
Alloxan 
Analysis of variance 
Anti-glutamic acid decaboxylate 
Animal Research and Service Centre 
Aspartate aminotransferase 
Body mass index 
Blood urea nitrogen 
Cordyceps sinensis 
Disability Adjusted Life Years 
Diabetes mellitus 
Dinitrosalicylic acid 
Fasting blood glucose 
Free fatty acid 
Fasting plasma glucose 
Gas Chromatography Mass Spectrometry 
Gestational diabetes mellitus 
Sulphuric acid 
Glycated haemoglobin  
Hydrochloric acid 
High density lipoprotein 
Half maximal inhibitory concentration 
xiv 
 
ICA 
IDF 
IDDM 
im 
ip 
iv 
K
+
ATP 
LDL 
LOD 
Na2CO3 
NAD 
ND 
NHMS 
NIDDM 
OGTT 
PPARγ 
Rpm 
SEM 
STZ 
TMC 
TTM 
WHO 
VLDL 
g 
g/day 
Islet cell antibody 
International Diabetes Federation 
Insulin-dependent diabetes mellitus 
Intramuscular 
Intraperitoneal 
Intravenous 
Sodium-potassium adenosine triphosphatase 
Low density lipoprotein 
Limit of detection 
Sodium carbonate 
Nicotinamide-adenine dinucleotide 
Not detected 
National Health Morbidity Survey 
Non-insulin dependent diabetes mellitus 
Oral glucose tolerance test 
Peroxisome proliferator-activated receptor-gamma 
Resource prospector mission 
Standard error mean 
Streptozotocin 
Traditional Chinese Medicines 
Traditional Tibetan Medicines 
World Health Organization 
Very low density lipoprotein 
Gram 
Gram per day 
xv 
 
Kg 
L 
ml 
mg/dL 
mg/kg/day 
mg/ml 
mmol/L 
U/day 
 
Kilogram 
Litre 
Millilitre 
Miligram per decilitre 
Milligram per kilogram per day 
Milligram per millilitre 
Milimol per litre 
Unit per day 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xvi 
 
PENYARINGAN FITOKIMIA DAN AKTIVITI ANTIHIPERGLISEMIK 
Cordyceps sinensis DAN PRODUK ASASNYA (ESULIN).  
 
ABSTRAK 
 
Diabetes mellitus merupakan satu gangguan metabolik umum dengan 
komplikasi vascular mikro dan makro yang mengakibatkan morbiditi dan kematian 
yang ketara. Kajian yang diterangkan di dalam tesis ini adalah satu usaha untuk 
menilai potensi antihiperglisemik ekstrak akues Cordyceps sinensis (C.sinensis) dan 
produk asasnya, Esulin. Tiga esperimen utama telah dijalankan untuk mencapai 
objektif umum. Esperimen pertama ialah mengenal pasti kelas fitokimia C.sinensis 
dan Esulin untuk menyediakan nilai terapeutik herba ini sebagai asas untuk 
penyelidikan selanjutnya. Penyaringan fitokimia untuk kedua-dua ekstrak telah 
dijalankan dengan menggunakan prosedur standard bagi pengesanan alkaloid, tanin, 
saponin, terpenoid dan flavonoid. Keputusan yang diperolehi secara positif 
menunjukkan kehadiran empat sebatian bioaktif utama iaitu alkaloid, saponin, tanin, 
dan flavonoid dalam kedua-dua C.sinensis dan Esulin. Selain itu, terpenoid hanya 
hadir di dalam Esulin. Bahagian kedua kajian ini adalah untuk menentukan kesan 
rencatan ekstrak akues C.sinensis dan Esulin terhadap aktiviti enzim alfa amilase dan 
alfa glukosidase. Kedua-dua ekstrak dan juga acarbose (ubat standard sebagai 
kawalan positif) dilarutkan dalam air suling dan disediakan pada lima kepekatan 
yang berbeza iaitu 0.125, 0.25, 0.5, 1 dan 2 mg/ml. Setiap analisis dilakukan tiga kali 
dan purata digunakan untuk mengira peratusan enzim perencatan. Dalam analisis in 
vitro ini, ekstrak akueus Esulin mempunyai aktiviti rencatan alfa amilase dan alfa 
glucosidase yang baik dengan nilai IC50 yang rendah dan menunjukkan perencatan 
peratusan tertinggi pada kepekatan yang diuji (2 mg/ml) berbanding ekstrak akueus 
C.sinensis. Kajian ketiga yang dijalankan ialah penilaian in vivo terhadap kesan 
xvii 
 
C.sinensis dan Esulin pada tikus diabetis aruhan streptozotocin. Tikus diberikan 
secara oral ekstrak akueus C.sinensis dan Esulin (75, 150, 300 mg/hari masing-
masing), metformin (150 mg/hari) dan Humulin R (5 U/hari) sekali sehari selama 28 
hari. Keputusan yang diperolehi daripada kajian ini menunjukkan bahawa ekstrak 
C.sinensis dan Esulin menurunkan paras glukosa darah, fruktosamin, jumlah 
kolesterol dan trigliserida tikus diabetis secara ketara (p < 0.05). Pemberian kedua-
dua ekstrak herba juga menyebabkan peningkatan ketara serum insulin dan kolesterol 
lipoprotein berketumpatan tinggi (HDL) apabila dibandingkan dengan tikus kawalan 
diabetis. Pada tikus aruhan diabetik, peningkatan glukosa darah disertai peningkatan 
tahap bilirubin, fosfat alkali (ALP), alanin amino transferes (ALT), aspartat 
aminotransferes (AST), urea dan kreatinin. Walaubagaimanapun, selepas rawatan 
dengan kedua-dua ekstrak bagi tempoh empat minggu, aktiviti serum bilirubin, ALP, 
urea dan kreatinin menunjukkan penurunan yang ketara. Penemuan ini adalah 
setanding dengan tikus diabetis yang menerima ubat standard, metformin dan 
Humulin R. Kesimpulannya, ekstrak akueus C.sinenis dan Esulin menunjukkan 
kesan antihiperglisemia dan hypolipidemia pada tikus diabetis dengan menurunkan 
paras glukosa darah, fruktosamin, kolesterol dan trigliserida dan pada masa yang 
sama dapat meningkatkan paras insulin dan kolesterol HDL. Kajian ini juga 
mencadangkan salah satu mekanisma potensi antidiabetis kedua-dua ekstrak ialah 
melalui perencatan alfa amilase dan alfa glukosidase. Walaubagaimanapun, 
mengambil kira semua data, kajian ini menunjukkan ekstrak akueus Esulin bekerja 
lebih baik berbanding C.sinensis dalam mengurus dan mengawal diabetes. Oleh itu, 
produk herba ini berpotensi menjadi calon untuk penyelidikan pembangunan ubatan 
pada masa hadapan terutama dalam rawatan diabetes mellitus.  
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PHYTOCHEMICAL SCREENING AND ANTIHYPERGLYCAEMIC 
ACTIVITIES OF Cordyceps sinensis AND ITS BASED PRODUCT (ESULIN).  
 
ABSTRACT 
 
Diabetes mellitus is one of the common metabolic disorders with micro and 
macro vascular complications that result in significant morbidity and mortality. The 
present study described in the thesis is an effort to evaluate the antihyperglycaemic 
potentials of the aqueous extracts of Cordyceps sinensis (C.sinensis) and its based 
preparation namely Esulin. Three main experiments were conducted to achieve the 
general objective. The first experiment identified the phytochemical classes of 
C.sinensis and Esulin in order to provide the therapeutic value of these herbs as a 
basis for further research. Phytochemicals screening for both extracts were carried 
out using the standard procedures for alkaloid, tannin, saponin, terpenoid and 
flavonoid detection. Results acquired positively showed the presence of four main 
bioactive compounds i.e. alkaloids, saponins, tannins, and flavonoids in both 
C.sinensis and Esulin. Additionally, terpenoids were only present in Esulin. The 
second part of this study was to determine the inhibitory effects of the C.sinensis and 
Esulin aqueous extracts on the activities of alpha amylase and alpha glucosidase 
enzymes. Both extracts as well as acarbose (standard drug as positive control) were 
dissolved in distilled water and were prepared at five different concentrations of 
0.125, 0.25, 0.5, 1 and 2 mg/ml. Each analysis was performed three times and the 
mean was used to calculate the percentage of enzymes inhibition. In this in vitro 
analysis, the aqueous extract of Esulin had good alpha amylase and alpha glucosidase 
inhibitory activity with the lowest IC50 value and showed the highest percentage 
inhibition at the concentration tested (2 mg/ml) compared to C.sinensis extract. The 
third study conducted was the in vivo assessment on the effects of C.sinensis and 
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Esulin on streptozotocin-induced diabetic rats. The rats were administered orally 
with the aqueous extracts of C.sinensis and Esulin (75, 150, 300 mg/day each), 
metformin (150 mg/day) and Humulin R (5 U/day) once daily for 28 days. Results 
obtained from this part of study indicated that C.sinensis and Esulin extracts 
significantly (p < 0.05) reduced the fasting blood glucose, serum fructosamine, total 
cholesterol and triglycerides levels of diabetic rats. Administration of both herbal 
extracts also caused significant increase in the serum insulin and high density 
lipoprotein (HDL)-cholesterol levels when compared to diabetic control rats. In 
diabetic-induced rats, the rose of blood glucose was accompanied by an increased in 
serum bilirubin, alkaline phosphatase (ALP), alanine aminotransferase (ALT), 
aspartate aminotransferase (AST), urea and creatinine levels. However, following 
treatment with both extracts for a period of four weeks, activities of serum bilirubin, 
ALP, urea and creatinine exhibited significant reduction. These findings were 
comparable with those receiving standard drugs, metformin and Humulin R. In 
conclusion, C.sinensis and Esulin aqueous extracts displayed antihyperglycaemic and 
hypolipidemic effects in diabetic rats by lowering blood glucose, serum 
fructosamine, cholesterol and triglyceride and at the same time can increase the 
levels of serum insulin and HDL-cholesterol. This study also suggests that one of the 
mechanisms for antidiabetic potential of both extracts is by the inhibition of alpha 
amylase and alpha glucosidase enzymes. However, taking all data together, this 
study revealed that the Esulin aqueous extract worked better compared to C.sinensis 
extract in managing and controlling diabetes. Thus, this herbal product could become 
the next potential candidate for drug development research, particularly in the 
treatment of diabetes mellitus. 
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CHAPTER 1 
 
INTRODUCTION 
 
 
1.1 Background 
 
Diabetes mellitus (DM) is a serious and chronic endocrine metabolic disorder 
characterised by persistent hyperglycaemia. It is caused by inadequate insulin either 
in its production or its function (American Diabetes Association (ADA), 2014; 
Kumar and Clark, 2002). Insulin deficiency leads to chronic hyperglycaemia with 
disturbances of carbohydrate, fat and protein metabolism (Beverley and Eschwege, 
2003; Manikandan et al., 2013). It has a significant impact on health, quality of life 
and life expectancy of patients even though it is regarded as a common and 
controllable disease (Kirkman et al., 2012). As a global burden, DM is recognised as 
one of the five major causes of morbidity in the world (Ahmed et al., 2010a) that 
leads to severe health complications such as neuropathy, retinopathy, nephropathy, 
cardiovascular complication and ulceration (Fowler, 2008; Soumya and Srilatha, 
2011). 
 
The epidemic of diabetes has enormously affects more than 382 million 
individuals throughout the world (Ramachandran et al., 2014; Sugathan et al., 2013). 
In year 2013, global estimates further growth of this disease for almost 50% with the 
greatest increase in the developing countries of Asia, South America and Africa 
(Zimmet et al., 2001). According to Diabetes Atlas of the same year (2013), the 
current highest number of people with diabetes are reported in the European and 
Western Pacific regions with 53 and 138 million, respectively (Chanet al., 2014). 
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However, by the year 2025, the South East Asia region is expected to have the 
greatest number of diabetes with the estimated prevalence of 13.5% or in number is 
145 million people (Letchuman et al., 2010). 
 
In Malaysia, diabetes progressively gained momentum over the decades. 
According to the World Health Organization (WHO), Malaysia is expected to have a 
total number of 2.48 million diabetic people in 2030 as compared to 0.94 million in 
year 2000 (Subramanian et al., 2008). The fact that, this statistic was worrying 
because among the top ten chronic diseases in the country, DM was ranked sixth for 
man and fifth for women according to the Disability Adjusted Life Years (DALYs) 
(Letchuman et al., 2010). With such scenario, DM was ranked at sixth place in the 
top 20 causes of death in Malaysia (Yusoff et al., 2013). WHO (2014) reported that 
this disease caused 4,750 or 3.74% of total deaths in the country, where Malaysia 
was ranked 95
th 
worldwide. This statistic showed that diabetes ranks higher than 
hypertension and lung cancer (WHO, 2014). 
 
The increasing prevalence of diabetes is not only regarded as a recent medical 
challenge but has contributed for a rapid increase in the cost of health care 
management of the particular disease and its chain complications over the last 
decade. The International Diabetes Federation (IDF) estimated around US$ 213 
billion and as high as US$ 396 billion will be spent on medical cost for this disease 
by year 2025 (Ali and Jusoff, 2009). It is calculated that there will be almost 50% 
increase in direct health care costs from year 2003 to 2025 (Ibrahim et al., 2010). In 
Malaysia, it was reported that the direct outpatient cost of diabetic patient per year 
was RM 802.15 for health clinic without specialist and RM 1127.00 for health clinic 
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with specialist (Ibrahim et al., 2010). Furthermore, it was revealed that the total costs 
of diabetic foot were RM 47373.70 per year. This charge only reflects the cost for 
managing an acute infection. However, the expenditure is estimated to escalate for 
outpatient follow up, physiotherapy and indirect costs of emotional suffering and 
reduced productivity (Lam et al., 2014).  
 
Despite the escalation of medical expenditure, there is still lacking of 
satisfactory and effective therapies for diabetes up to the moment (Ahmed et al., 
2010a; Ghosh and Suryawanshi, 2001). Although insulin therapy and other          
non-insulin medications can control many aspects of DM, there are numerous 
drawbacks include hypoglycaemia, gastrointestinal disturbances, weight gain, 
nausea, oedema, as well as kidney and liver complications which are commonly 
experienced among diabetic patients (Piedrola et al., 2001). Hence, there is an urgent 
need to use multiple medications with acceptable tolerability and safety profiles. This 
aims to reduce the risk of serious adverse events including kidney and liver diseases, 
blindness, vascular and neurological problems that can lead to amputation and 
increased mortality (Cade, 2008). 
 
For centuries there are growing interest in the use of medicinal plants as an  
alternative management for various chronic diseases including DM. Ethnobotanical 
reports have stated that, approximately 800 plants are being utilised as traditional 
remedies for the diabetes treatment, but many of them do not have scientific 
explanation (Aguilara et al., 1998; Pushparaj et al., 2000). To the present day, the 
medicinal values of various plant extracts have also been continuously studied by 
many diabetic research scientists worldwide (Daisy and Eliza, 2007; Lodha et al., 
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2010; Noor et al., 2008). From that, plenty of traditional plant preparations 
particularly the compounds with both hypoglycaemic and antioxidative properties 
have been selected for the development of antidiabetic agents (Day, 1998). 
 
Among various medications and alternative medicines, several herbs have 
been known to cure and control diabetes. Cordyceps sinensis (C.sinensis) is one of 
the most valued herbs in the traditional Chinese medicine, which has a broad 
application in diabetes treatment. C.sinensis is classified as an Ascomycetes fungus 
and has been reported to possess various pharmacological actions, such as anti-
inflammatory (Yu et al., 2004), antitumor (Nakamura et al., 1999), hypolipidemic 
(Koh et al., 2003), anti-aging (Ji et al., 2009) and hypoglycaemic (Kiho et al., 2000). 
The popularity of C.sinensis is manifested by the emergence of many commercial 
products in the local and international market including Esulin. The product of Esulin 
also contains small amounts of other herbs and it has been formulated to be a 
potential candidate for the management of DM which is increasing rapidly in 
Malaysia. 
 
1.2 Scope of the study 
 
In this present study, C.sinensis was evaluated for its phytochemical analysis 
and antidiabetic activities both in vitro and in vivo. This herb was chosen due to its 
popularity as been widely utilised as antidiabetic agent and for treating various 
ailments. Although there are several previous experiments of the antidiabetic 
activities of C.sinensis (Fatma El Zahraa et al., 2012; Kiho et al., 2000; Lo et al., 
2006; Zhang et al., 2006), but this current work is different in various aspects. This 
study focused on evaluation of the effectiveness between C.sinensis compared to its 
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based product, Esulin particularly on their in vitro and in vivo antidiabetic activities 
and fairly important was the analysis of their phytochemical classes. 
 
Therefore, this present study was divided into three phases as listed below:- 
a) Study I:- Screening of phytochemicals of the aqueous extracts of C.sinensis 
and its based product, Esulin. 
This experiment was conducted to determine the classes of secondary plant 
metabolites that present in both aqueous extracts of C.sinensis and Esulin. 
 
b) Study II:- In vitro antidiabetic activity of the aqueous extracts of C.sinensis 
and its based product, Esulin. 
This in vitro antidiabetic study was investigated using alpha amylase and 
alpha glucosidase inhibition assays. 
 
c) Study III:- In vivo antidiabetic activity of the aqueous extracts of C.sinensis 
and its based product, Esulin. 
This last phase of experiment was the confirmatory in vivo antidiabetic 
studies of both extracts that were eventually conducted in streptozotocin 
induced diabetic rats. 
 
This set of study was aimed to generate a stronger pharmacological rationale 
towards understanding the efficacy of these extracts as potential antihyperglycaemic 
candidates. 
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1.3 Objectives of the study 
 
1.3.1 General objective 
 
The general objective of this study was to evaluate the potential 
antihyperglycaemic activities of the aqueous extracts of C.sinensis and its based 
formulation (Esulin) on management of diabetes. 
1.3.2 Specific objectives 
 
 The specific objectives of this study are listed as follow:- 
1. To identify the classes of secondary plant metabolites present in the aqueous 
extracts of C.sinensis and Esulin from the phytochemical screening analysis 
by means of Study I. 
 
2. To assess the in vitro alpha amylase and alpha glucosidase inhibiting 
activities of the aqueous extracts of C.sinesis and Esulin by means of Study 
II. 
 
3. To investigate the effects of aqueous extracts of C.sinensis and Esulin on the 
management of diabetes in streptozotocin (STZ) induced diabetic rats by 
means of Study III. 
 
 
 
 
 
7 
 
1.4 Importance of study 
 
As the prevalence of DM is increasing, more research on alternative 
treatments based on natural resources need to be further investigated. However, one 
of the major problems with herbal medicine is lacking definite and complete 
information about the composition of extracts and there is little biological knowledge 
on the action of diabetes treatment. 
 
With regards to the present study, scientific information on the types of a 
phytochemical group of C.sinensis and its based product, Esulin are not widely 
available. Thus, the identification of the constituents classes performed in this study 
is crucial to assist in the analysis of the therapeutic efficacy of these herbs. 
 
Apart from this, the limited scientific literature pertaining to the in vitro 
antidiabetic activities of C.sinensis and Esulin enhance the urgency of conducting 
this present research. This in vitro investigation is fairly important to rule out the 
antidiabetic effects of both herbs on particular digestive enzymes. The encouraging 
findings of the enzymes inhibition assays pave way for the confirmatory in vivo 
study. 
 
As in most efficacy studies, the in vivo experiment is necessary to be 
conducted in a complete body-system model in order to relatively substantiate the   
in vitro findings. Hence, the antidiabetic activities of both C.sinensis and its based 
product were finally investigated in experimental diabetic rats prior to the 
confirmation of the antidiabetic potential of these aforementioned herbs. 
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The information gathered from this study could be utilised as an initial 
scientific platform for the scientific community in particular, as well as for the public 
in general. This study could initiate other comprehensive research in order to develop 
a safe antidiabetic agent. Further, this research can also indirectly enlighten 
consumers about the potential efficacy of C.sinensis and Esulin. This will help in 
ensuring better understanding among the public and expanding new knowledge 
regarding these herbal formulations. 
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Figure 1.1 Experimental design of the overall study. The experiment comprised of    
screening of phytochemicals, the in vitro and in vivo studies of 
C.sinensis and its based product, Esulin. 
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CHAPTER 2 
 
LITERATURE REVIEW 
 
 
2.1      Diabetes mellitus 
 
The phrase „diabetes mellitus‟ is originally derived from the Greek words dia 
(= through) and bainen (= to go). The word mellitus (honey sweet) was added by 
Thomas Willis, a physician from Britain in 1675 after rediscovering the sweetness of 
urine and blood of patients. It was only in 1776 that Dobson from Britain firstly 
confirmed the presence of excess sugar in urine and blood as a cause of their 
sweetness (Ahmed, 2002). 
 
WHO reported that diabetes will be the seventh leading cause of death in 
2030 (Sugathan et al., 2013). The escalation trend in the number of patients with 
diabetes due to many factors such as population growth, aging urbanization, 
increasing the prevalence of obesity and physical inactivity (Wild et al., 2004). In 
fact, 90% of diabetic individuals have type 2 (non-insulin dependent) DM. Within 
this category, no more than 10% can be accounted for other rare forms of diabetes 
that are directly inherited (Pozzili and Di Mario, 2001). 
 
In our country, the earliest diabetes study was carried out in 1960 (Pillay and 
Lim, 1960) and in 1966 (West and Kalbfleisch, 1966). The first National Health and 
Morbidity Survey (NHMS) in Malaysia was carried out in 1986, where prevalence of 
diabetes among adults age 35 years old and above was found about 6.3% (NHMS, 
1986). Within ten years later, in the NHMS II, the figure had increased to 8.3% 
which was among adults of age 30 years old and above as shown in Figure 2.1 
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(Letchuman et al., 2010). This shocking rise had encouraged the Ministry of Health 
Malaysia to initiate numerous national healthy lifestyle campaigns. Thus, a national 
steering committee was set up to improve the screening and management of DM 
among residents in primary and secondary care clinics. 
 
 
Figure 2.1 Prevalence of diabetes mellitus by age group in Malaysia 
Source from Letchuman et al., (2010). 
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2.1.1 Major classifications of diabetes mellitus 
 
The WHO (1980) classified diabetes based on the clinical characteristic, 
where there are two common types of diabetes, which are insulin-dependent diabetes 
mellitus (IDDM) and non-insulin dependent diabetes mellitus (NIDDM). The WHO 
classification also recognises malnutrition related DM, which is other type of DM 
associated with specific conditions. Further is gestational diabetes which is diabetes 
diagnosed during pregnancy. There is a comparison of two major types of DM (type 
1 and type 2) as shown in Table 2.1. 
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Table 2.1 Comparison between type 1 and type 2 diabetes mellitus 
Features Type 1 Type 2 
Usual age of onset Childhood/ young 
adulthood 
Middle age or later 
Body build Normal Overweight 
Plasma insulin  Absent  Normal/high 
Complications  Ketoacidosis  Hyperosmolar coma 
Response to insulin  Normal  Reduced  
Response to oral 
antidiabetic 
Unresponsive  Responsive  
        Source from Alberti and Zimmet (1998). 
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2.1.1.1 Type 1 diabetes mellitus 
 
Type 1 DM represents around 5-10% of all cases of diabetes, effecting 
approximately around 20 million people worldwide (Maahs et al., 2010). Type 1 
diabetes also known as juvenile diabetes or IDDM and it is usually diagnosed in 
childhood and adolescence. Type 1 is caused by an absolute deficiency of insulin, 
usually as the result of a T-cell mediated autoimmune destruction of the β-cells of the 
pancreas. Insulin is a hormone that is required to allow sugar (glucose) to enter the 
cell and produce energy. The two main forms of clinical type 1 DM are type 1a 
which is thought to be due to immunological destruction of pancreatic β-cells, which 
is resulting in insulin deficiency (Foulis et al., 1991). Type 1a is characterized by the 
presence of islet cell antibody (ICA), anti-glutamic acid decaboxylate (anti-GAD), 
insulin antibodies that identify the autoimmune process with β-cell destruction 
(Epstein et al., 1994). Another one istype 1b (idiopathic), on the other hand, is the 
condition where there is no evidence of autoimmunity. There is no known etiological 
basis for type 1b DM, some of patients have permanent insulinopaenia and tend to be 
ketoacidosis, but have no evidence of autoimmunity (McLarty et al., 1990). 
 
Various factors may contribute to type 1 DM, including genetics and 
environment. Although the genetic susceptibility to type 1 DM is inherited, only 12% 
to 15% of type 1 diabetes occurs in families. This indicates that genetic factors do 
not account entirely for the development of type 1 DM. Thus, environment plays a 
primary factor that triggers type 1 diabetes patients through viral infections, 
nutritional factors, low birth weight and parental age (Akerblom et al., 2002). 
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2.1.1.2 Type 2 diabetes mellitus 
 
Type 2 DM or NIDDM is the most common type of diabetes, affecting 
almost 5% to 7% of the world‟s population (Amos et al., 1997; King et al., 
1998).The prevalence of diabetes is increasing rapidly. The WHO has predicted that 
by year 2030 the number of adults with diabetes worldwide will be more than 
doubled from 171 million in 2000 to 366 million (Wild et al., 2004). The incidence 
of type 2 DM increases with age and it is common in individuals over the age of 40. 
However in some specific ethnic such as African-American, Asian-Pacific and 
American Indians show that type 2 diabetes is increasing among children and it is 
common than type 1 DM (Cockram, 2000). It is often related with obesity (BMI >25 
kg/m2), decreased physical activity and genetic predisposition (Zimmet et al., 1990). 
In general, the rate of type 2 DM is higher in urban populations than rural 
communities (King et al., 1998) because it is associated with population, whose 
lifestyle has changed from traditional patterns to a modern (Bloomgarden, 1996). 
 
Type 2 DM is a heterogeneous disorder that results from an interaction 
between a genetic predisposition and environmental factors, that leads to the 
combination of insulin deficiency and insulin resistance (DeFronzo et al., 1997). 
Decreased insulin secretion and decreased insulin sensitivity are both involved in the 
onset of type 2 DM but the proportion of their involvement differs according to the 
patient. Pancreatic β-cell function is retained to a certain degree and insulin 
injections are rarely required for survival. Though, complications such as infection 
can lead to ketoacidosis temporarily but can arise with stress associated with another 
illness such as infection (Abate and Chandalia, 2003). 
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In fact, regular physical activity, healthy diet, maintaining a normal body 
weight and avoiding tobacco use are important components in the management of 
type 2 DM when blood glucose level cannot be controlled (Sugathan et al., 2013). 
Patients are advised to use oral hypoglycaemic agents or insulin as treatments of 
DM. Based on United States National Institutes of Health, exercise and diet are the 
essential strategies to reduce body weight, improve glycaemic index and also reduce 
risk of cardiovascular complication, which show approximately 70% to 80% of 
mortality among those with type 2 DM. It has been shown that weight reduction and 
increment in daily energy expenditures will improve glucose tolerance and decrease 
insulin resistance (Staffers et al., 1997). Based on epidemiological prospective study, 
regular physical activity performed several times a week has been associated with a 
decreased incidence of the disease in long term for both men and women at different 
age groups (Ross et al., 2000). 
2.1.1.3 Gestational diabetes mellitus 
 
Gestational diabetes mellitus (GDM) is a carbohydrate intolerance associated 
with hyperglycaemia of variable severity with the onset or first recognition of 
glucose intolerance during pregnancy, which usually occur during  the second or 
third trimester (ADA, 2003). In early pregnancy, fasting and postprandial glucose 
concentrations are normally lower than women, who are not pregnant. Individual 
with high risk of GDM includes older woman, woman with previous history of 
glucose intolerance, woman with history of babies larger for gestational age, woman 
from certain ethnic groups of higher risk for type 2 DM and any pregnant woman 
who has any elevation of fasting or casual blood glucose levels (WHO, 1999b). It is 
established that GDM can be harmful to both foetus and mother. It will increase the 
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risk of intrauterine foetal death during the last four to eight weeks of gestation and 
also causes other complications, including congenital abnormalities (Comess et al., 
1969). It occurs in about 4% of all pregnancies and patients with GDM have a 30% 
to 50% chance of developing type 2 DM later in life (Salim, 2005). 
2.1.1.4 Other specific types of diabetes mellitus 
 
Other specific types are small minority of cases estimated at about 2%, arise 
as the consequence of some other well-defined disease or predisposing factors such 
as pancreatitis or steroid excess (ADA, 2001). This category includes variety types of 
diabetes that is secondary to other specific conditions or associated with particular 
diseases or syndromes with a distinct aetiology. The categories and the causes of the 
other types of diabetes are shown in Table 2.2. 
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Table 2.2 Other specific types of diabetes mellitus 
Types  Diseases/syndromes 
1) Genetic defects of β-cell function Chromosome 20,HNF4α (MODY1) 
Chromosome 7,glucokinase (MODY2) 
Chromosome 12,HNF1α (MODY3) 
Chromosome 13,IPF1 (MODY4) 
Chromosome 17,HNF3β (MODY5) 
Mitochondrial DNA, A3243G mutation 
2) Genetic defects in insulin action Type A insulin resistance 
Leprechaunism 
Rabson-Mendenhall syndrome 
Lipoatrophic diabetes 
3) Others genetic syndromes sometimes  
associated with diabetes 
Down syndrome 
Friedreich ataxia 
Huntington disease 
Klinefelter syndrome 
Laurence-Moon-Biedl syndrome 
Myotonic dystrophy 
Porphyria 
Prader-Willi syndrome 
Turner syndrome 
Wolfram syndrome 
4) Uncommon forms of immune 
mediated diabetes 
Insulin autoimmune syndrome     
(antibodies to insulin) 
Anti insulin receptor antibodies 
Stiffman syndrome 
5. 5) Diseases of the exocrine  
pancreas 
Fibrocalculous pancreatopathy 
Pancreatitis 
Trauma/pancretectomy 
Neoplasia 
Cystic fibrosis 
Hemochromatosis 
Wolcott-Rallison syndrome 
6. 6) Endocrinopathies Crushing syndrome 
Acromegaly 
Pheochromocytoma 
Glucogonoma 
Hyperthyroidism 
Somatostatinoma 
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7. 7) Drug or chemical induced Nicotinic acid 
Glucocorticoids 
Thyroid hormone 
α-adrenergic agonist 
β-adrenergic agonist 
Thiazides 
Phenytoin 
Pentamidine 
Pyriminil (Vacor) 
Interferon-α 
8) Infections Congenital rubella 
Cytomegalovirus 
 
Sources from WHO (1999b). 
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2.1.2 Diagnosis of diabetes mellitus 
 
 Diagnosis of DM is the process of confirming that subject conforms to the 
disease concept. DM is diagnosed on the basis of the WHO recommendations from 
year 1999, which is incorporating both fasting plasma glucose and 2 h plasma 
glucose levels after 75 g oral glucose tolerance test (OGTT) into a practicable 
diagnostic classification (WHO, 1999a) (Table 2.3). If the fasting plasma glucose 
level is in the diagnostic range for diabetes, an OGTT is not required for diagnosis. A 
confirmatory test should be performed because a diagnosis of diabetes carries 
considerable and lifelong consequences for the patients as intraindividual variation or 
incomplete fasting may result in invalid diagnosis (Alberti and Zimmet, 1998). 
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Table 2.3 The 1999 World Health Organization diagnostic criteria for diabetes 
Glucose concentration  (mmol/L) 
Diabetes mellitus (DM) Fasting ≥ 7.0 or 2h post glucose load ≥ 11.1 
Impaired glucose tolerance Fasting ( if measured) < 7.0 and 2h post 
glucose load ≥ 7.8 and< 11.1 
Impaired fasting glucose Fasting ≥ 6.1 and < 7.0 and 2h post glucose 
load (if measured) < 7.8 
Glucose load = 75 g glucose orally 
Source from WHO (1999a). 
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2.1.3 Symptoms of diabetes mellitus 
 
 Symptoms are similar for both type 1 and type 2 DM but they are different in 
their intensity. Symptoms develop more rapidly and typical in type 1 DM. These 
include polydipsia, polyphagia, polyurea, weight loss, fatigue, cramps, blurred 
vision, constipation and candidiasis (Kumar and Clark, 2002). Although symptoms 
of type 2 DM are similar but insidious in onset. Most cases are diagnosed because of 
complications or incidentally. Type 2 DM carries high risk for large vessel 
atherosclerosis, which is commonly associated with hypertension, hyperlipidaemia 
and obesity (Saely et al., 2004; Svensson et al., 2004; Zimmet et al., 1990). In early 
stages of the disease, the symptoms may be deficient but unfortunately the damage to 
organs occurs even in the absence of symptoms. For this reason, it is important for 
the community who may be at risk for diabetes to get their blood sugar level checked 
regularly. Those at risk include people age 40 and above, overweight or obese, 
anyone with parent or sibling who has diabetes and woman who has diabetes during 
pregnancy or a baby weighing more than 4 kg at birth (Alberti and Zimmet, 1998). 
2.1.4 Complications associated with diabetes mellitus 
DM is a long term disorder associated with a number of clinical problems that 
causing ill and mortality. Complications of DM can be divided into two categories, 
which are microvascular and macrovascular diseases. The diseases affect the small 
blood vessels in the retina, kidney, and peripheral nerves which appear to be most 
directly related to the duration and severity of the raised blood glucose 
(hyperglycaemia). Microvascular complications of DM may result in blindness, 
chronic renal failure and nerve damage to the feet contributing to the formation foot 
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ulceration and amputation. Macrovascular diseases on the other hand occur when 
large blood vessels in heart, brain and peripheral circulation are affected. Therefore, 
people with DM have higher rates of getting stroke, heart disease and peripheral 
vascular disease compared to normal people of the same age and sex (Kannel and 
McGee, 1979). 
 
One of the most important complications of DM is it can affect the eye 
through the development of retinopathy. This common complication cause blindness 
and responsible for 10,000 new cases of blindness every year in the United States 
(Fong et al., 2004). The prevalence of diabetic retinopathy in Malaysia has been 
reported progressively rise and much higher than the figures reported from U.K 
Australia and Japan (Tajunisah et al., 2011). The main risk of developing diabetic 
retinopathy and other complications of DM depends on both duration and severity of 
the patient with hyperglycaemia. According to literature, the severity of 
hyperglycaemia and uncontrolled hypertension are the crucial factors for the 
development of diabetic retinopathy in patients with type 2 DM. It is begins to 
develop as early as seven years prior to the diagnosis of diabetes in these patients 
(Fong et al., 2004). Most patients with type 1 diabetes on the other hand develop 
evidences of retinopathy within 20 years of diagnosis (Keenan et al., 2007). 
 
Another complication of DM is diabetic nephropathy, which is the most 
common cause of established renal failure by damaging small blood vessels in 
kidney. This difficulty is one of the leading causes of morbidity and mortality in 
diabetic patient. The initial stage of diabetic nephropathy is microalbuminuria, which 
is defined as albumin excretion of 30-299 mg/24 hours higher than normal albumin 
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excretion (<20 mg/24 hours) (Fowler, 2008). Usually, diabetic patients with 
microalbuminuria will develop proteinuria and overt diabetic nephropathy, as this 
progression occurs in both types 1 and 2 DM. It affects about 30% of people with 
type 1 DM, typically appearing about 10 years after diagnosis. In those with type 2 
diabetes, it tends to be appearing after a shorter time scale (Thomas, 2003). Like 
other microvascular complications of DM, patients should be treated to the lowest 
safe glucose level and normalization of blood pressure must be obtained to prevent or 
control diabetic nephropathy (Adler et al., 2003; Gross et al., 2005). 
 
Diabetes also results in neuropathy which is a damage of the peripheral 
nervous system or the network of nerves. According to the ADA (2007), diabetic 
neuropathy is a symptom and/or signs of peripheral nerve dysfunction in the patient 
with diabetes after the exclusion of other causes. Neuropathy affects around 20% to 
50% of patients with type 2 DM and out of this more than 75% of amputations occur 
after developing foot ulceration (Boulton et al., 2005). Diabetic neuropathy can be 
divided into several different forms, including acute reversible and other persistent 
neuropathies, such as symmetrical, focal or multifocal and autonomic neuropathies. 
From that, symmetrical neuropathy also known as peripheral neuropathy is damage 
to the axon tips that begin in the longest nerves and has become the most common 
form among diabetic patients. In this condition, patients lose their sense to light 
touch, vibration and temperature and it leads to numbness (Fowler, 2008). However, 
there is no specific treatment of diabetic neuropathy, although many drugs are 
available to treat these symptoms. 
 
